Background The purpose of this study was to compare combination antithrombotic therapy with aspirin plus anticoagulation versus aspirin alone, when added to conventional antianginal therapy in patients with unstable rest angina or non-Q-wave myocardial infarction who were nonprior aspirin users.
Methods and Results Two hundred fourteen patients were randomized; 109 were randomized to receive aspirin alone (162.5 mg daily) and 105 to receive a combination of aspirin plus anticoagulation, ie, aspirin 162.5 mg daily plus heparin (activated partial thromboplastin time, two times control) followed by aspirin 162.5 mg daily plus warfarin (international normalized ratio, 2 to 3). Trial therapy was begun by 9.5 +8.8 hours of qualifying pain and was continued for 12 weeks. Primary end points were recurrent angina with ECG changes, P5 atients with unstable angina pectoris represent a broad spectrum, ranging from progressive or accelerating angina to the higher-risk subset of rest angina with reversible ECG changes.' Biochemical studies in humans2'3 and studies in an experimental animal model4,5 suggested a major role for platelets and platelet-derived thromboxane A2 in this syndrome. Randomized, therapeutic clinical trials have established a beneficial role for antiplatelet agents in unstable angina or non-Q-wave myocardial infarction. [6] [7] [8] [9] In contrast, therapy with either antiplatelet agents alone or anticoagulants alone are of benefit in the acute coronary syndromes of unstable angina and/or non-Q-wave myocardial infarction.
Pathoanatomic and biochemical observations implicate platelet-rich thrombus overlying a ruptured plaque as the triggering mechanism for these acute coronary syndromes. 13-'7 In an experimental model of deep arterial injury (mimicking plaque rupture), Lam et al18 observed a significant reduction in platelet deposition and mural thrombus in animals pretreated with aspirin plus heparin versus heparin alone. The prior clinical trials have shown that failure of medical therapy in these syndromes most often occurs within the first few days after admission.8"1"9 Therefore, in view of the dynamic intra-arterial processes precipitating unstable angina and non-Q-wave infarction, more aggressive antithrombotic therapy with platelet inhibition plus anticoagulation may offer more benefit than either agent alone. Based on the trend to lower mortality and morbidity with combination therapy in the RISC8 study and in the small pilot study of Treatment Protocol: Trial Antithrombotic Therapy
Patients were randomized to receive one of two treatments. Aspirin alone. Upon randomization, 162.5 mg aspirin PO as a loading dose followed by 162.5 mg aspirin daily.
Aspirin plus anticoagulation. Upon randomization, 162.5 mg aspirin PO and a loading dose of 100 U/kg heparin IV bolus. This was followed by 162.5 mg aspirin daily plus a continuous heparin infusion to maintain the activated partial thromboplastin time (aPTT) at two times control for 3 to 4 days. The aPTT tests were drawn 6 hours after the initial bolus and then once daily. Warfarin was to be started by the second or third day, presuming that coronary arteriography did not appear imminent. When the international normalized ratio (INR) reached 2.0 to 3.0 (prothrombin time, about 1.3 to 1.5 times control), heparin was discontinued.
Treatment Protocol: Standard Medical Therapy
In addition to trial antithrombotic therapy, antianginal therapy was administered to all patients according to the following algorithm. Patients not taking a ,3-blocker were defined as low-risk or higher-risk. Low-risk patients had a normal ECG at the time of randomization and no previous myocardial infarction; therapy administered was metoprolol 50 mg PO immediately followed by 50 to 100 mg BID, plus oral isosorbide dinitrate (ISDN) 20 to 40 mg every 6 hours. Higher-risk patients received metoprolol 50 mg PO immediately followed by 50 to 100 mg BID, plus oral ISDN 20 to 40 mg every 4 to 6 hours, plus nifedipine 10 to 30 mg three times daily as tolerated. If 13-blocker use was contraindicated, diltiazem 30 mg QID increasing to 60 to 90 mg QID as tolerated plus ISDN 20 mg every 4 to 6 hours was given. Patients already taking a 3-blocker were given maximized 3-blockade, maximized nitrates, and nifedipine 10 to 30 mg TID orally. If pain recurred in the hospital on the above regimen, oral nitrates were discontinued, and intravenous nitroglycerin (5 ,ug/min) or ISDN (2 mg/h) (increasing to maximum tolerated, as clinically indicated) was substituted.
The doses of the antianginal drugs were maximized as tolerated within 48 hours in order to titrate the systolic blood pressure to < 130 mm Hg and the heart rate to c65 beats per minute. Aspirin-containing medication other than trial drug was prohibited, and a supply of acetaminophen was given. In the absence of a revascularization procedure, patients were discharged on their antianginal regimen plus their trial antithrombotic therapy.
Withdrawal of Trial Therapy
Trial therapy was discontinued for the following reasons: (1) major bleeding defined as transfusion of two or more units of blood, surgical correction, retroperitoneal or intracranial hemorrhage, or bleeding resulting in death or permanent disability, (2) minor bleeding that the study physician believed could not be remediated by adjusting the dose of antithrombotic therapy, (3) development of an end point (recurrent ischemia, myocardial infarction, or death) or of a cerebrovascular accident, (4) if after trial therapy was begun, a patient was found to have normal coronary arteries, nonobstructive coronary artery disease (no lesions .50%), or a negative maximal exercise tolerance test, or there was a clear reason other than progressive ischemic heart disease for the qualifying pain, eg, severe anemia unrecognized at the time of randomization, trial therapy was discontinued; if a patient was determined to have had a transmural infarction as the qualifying event, eg, a true posterior infarction, trial therapy was also discontinued, (5) surgical revascularization or angioplasty, (6) noncompliance with trial medication or missing two consecutive follow-up visits.
Data Collected
Enrolled patients were seen by the study team upon admission, during their hospitalization, at the time of hospital discharge, 1 week after discharge, and thereafter at 3-week intervals for a total of 12 weeks. P=.02). The mean age of the 214 patients was 61 years.
primary event compared with 20 patients (19%) asOne hundred forty-seven patients were admitted for signed to aspirin plus anticoagulation (P=.09 by log unstable angina, 46 with a non-Q-wave myocardial rank statistic after adjusting for history of hypertension infarction, and 16 with an evolving Q-wave infarction.
and diastolic blood pressure at entry) ( Table 2 and Five patients had no cardiac enzyme information at Figure) . When exposure was censored at the time that a baseline.
patient discontinued trial therapy, 27 patients (25%) By the end of the 12-week follow-up period, 31 assigned to aspirin experienced a primary event compatients (28%) assigned to aspirin alone experienced a pared with 14 patients (13%) assigned to aspirin plus anticoagulation (P=.06 by log rank statistic after adjusting for history of hypertension and diastolic blood pressure at entry). Post hoc analysis by intention to treat, limiting exposure to 14 days (as if the study had been designed as an acute phase trial), showed a significant benefit for combination therapy (Table 3) : 27% of patients assigned to aspirin experienced a primary event versus 10% of patients assigned to combination therapy (P=.004 by log rank statistic, after adjusting for history of hypertension and diastolic blood Graph shows cumulative percent of patients free of any primary end point. Also depicted in the bottom half of the panel is the withdrawal rate from trial therapy. AC indicates anticoagulant. .03 *After adjustment for history of hypertension and diastolic blood pressure at entry. pressure at entry), yielding a relative risk of 0.35 (95% confidence interval, 0.17 to 0.72).
Unstable Angina Versus Non-Q-Wave Myocardial Infarction
One hundred forty-seven patients were classified as being admitted with unstable angina, and 46 patients were classified as having an admission non-Q-wave myocardial infarction. In the unstable angina subset, 22 of 76 patients assigned to aspirin alone had a primary event (29%) versus 15 of 71 assigned to aspirin plus anticoagulation (21%). In the non-Q-wave infarction subset, 7 of 22 patients assigned to aspirin alone had a primary event (32%) versus 4 of 24 assigned to aspirin plus anticoagulation (17%). However, all of the primary events experienced by the non-Q-wave infarction patients occurred within the first 14 days.
Secondary End Points
In the aspirin-alone treatment group, 16 patients (15%) underwent revascularization with either PTCA or CABG versus 12 (11%) in the aspirin-plus-anticoagulation group. With reference to major bleeding complications, there were no spontaneous (unrelated to coronary revascularization) major bleeds in the patients assigned to aspirin alone. In contrast, in the patients assigned to combination therapy, the major bleeding rate was 2.9%. The frequency of minor bleeds or medication intolerance in patients assigned to aspirin alone versus combination therapy was 2.8% and 6.7%, respectively. Withdrawals
Withdrawal from therapy or occurrence of a secondary end point occurred in 31% of patients assigned to aspirin alone and in 45% of patients assigned to combination therapy before the end of the 12 weeks of follow-up. The reasons for withdrawal of therapy varied ( In patients not taking aspirin, our data suggest that combination antithrombotic therapy significantly reduces the incidence of primary ischemic events in the early phase (first 14 days). However, by 90 days, there is only a trend favoring combination therapy. It is possible that the power to detect a significant difference at 90 days using an intention-to-treat analysis was too small, given our sample size.
Comparison With Prior Studies
Combination therapy for unstable angina or non-Qwave infarction has been prospectively evaluated in only three studies.8,11 '19 The trial by Theroux et all' was the first randomized comparison of different antithrombotic regimens including combination therapy with aspirin plus heparin in patients with unstable angina. Trial therapy was terminated after a mean follow-up of 6 days. Combination therapy with aspirin plus heparin was significantly better than placebo; however, there were no statistically significant differences in recurrent ischemic events between the combination group versus the heparin-alone or aspirin-alone treatment limbs. '1 The RISC Study Group8'20 conducted a 90-day study of combination low-dose aspirin (75 mg daily) and heparin versus aspirin alone or versus heparin alone in patients with either unstable angina or non-Q-wave infarction. The heparin treatment was only continued for 5 days. The combination of aspirin and short-term heparin resulted in the lowest rate of events at 5 days, but there were no significant differences in recurrent ischemic events between the combination group versus the aspirin-alone treatment limbs. 8 The relative risk reduction in infarction or death occurring within the first 5 days in patients on combination therapy versus aspirin alone was similar for these two trials (Theroux et al,1" RISC8) as well as the present ATACS study (Table 5 ). The pooled estimate of the relative risk combining observed results from the three studies (calculated using the method of Mantel-Haensze121) for infarction or death among patients treated with combination antithrombotic therapy compared with aspirin alone was 0.44 (95% confidence interval, 0.21 to 0.93).
Combination antithrombotic therapy with aspirin plus anticoagulants has also been shown to be more effective than anticoagulants alone in reducing thromboembolism in patients with prosthetic heart valves. [22] [23] [24] The recent randomized trial of Turpie et a125 demonstrated a highly significant reduction in thromboembolism with combination therapy.
The higher ischemic event rate experienced in our study, compared with RISC or Theroux et al, may be partially explained by the fact that randomization and treatment in our study occurred at the time of admission in the emergency room. In the RISC Study,8 randomization was allowed up to 72 hours after hospital admission. In the Theroux study," only the events occurring within the first 5 days were counted, and patients with non-Q-wave infarction were excluded. Our data indicate that recurrent ischemic events may occur within days of onset of pain. Therefore, any delay in randomization may overlook patients with early recurrent ischemia and artificially reduce the total number of events.
Non-Q-Wave Myocardial Infarction
The impact of combination therapy on the subset of patients with non-Q-wave infarction paralleled that for patients with unstable rest angina in that there appeared to be a trend in favor of combination therapy. It has been suggested that the stimulus for clot propagation in these patients is greater than in patients with unstable angina.'7 This may explain why, despite initiating trial antithrombotic therapy within 24 hours, even in combination, almost all recurrent ischemic events in patients with non-Q-wave infarction occurred within the first 14 days. 26 
Clinical Implications
In summary, the dynamic intra-arterial process precipitating the acute coronary syndromes of unstable rest angina and non-Q-wave myocardial infarction necessitates prompt and aggressive antithrombotic therapy with aspirin plus an anticoagulant. In the absence of trials showing that urgent revascularization with either PTCA27 or urgent CABG2829 reduces acute morbidity or improves long-term survival compared with aggressive medical management, we believe that the combination antithrombotic regimen added to antianginal medication should become the standard, early-phase medical regimen for these acute coronary syndromes. A more effective antithrombotic therapy must be identified for prior aspirin users and for patients with non-Q-wave infarction.
